This study consists of 2 parts. Part 1 of the study is conducted to evaluate the efficacy,
safety, and tolerability of two doses of K0706 compared to placebo in subjects with early
Parkinson's Disease who are not receiving dopaminergic therapy. Part 2 is an optional long
term extension study for subjects who have completed week 40 of Part 1
This study is designed to assess the ability of K0706 to slow the progression of PD.
Preclinical animal model data have already demonstrated that K0706 has neuroprotective
activity, but further development will require human clinical experience.
This study will also allow determination of safety and tolerability of K0706 over many months
in subjects with PD.
Early Parkinson Disease, Parkinson's Disease, Parkinson Disease
If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.
Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.